Amgen (NASDAQ: AMGN) revenue
Amgen reported revenue of $36,751m for fiscal 2025, 10.0% more than in fiscal 2024 ($33,424m). Since fiscal 2016 its revenue has grown by 59.8%, an average growth of 5.4% a year.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $36,751m | +10.0% | $9,080m | 24.7% |
| 2024 | $33,424m | +18.6% | $7,258m | 21.7% |
| 2023 | $28,190m | +7.1% | $7,897m | 28.0% |
| 2022 | $26,323m | +1.3% | $9,566m | 36.3% |
| 2021 | $25,979m | +2.2% | $7,639m | 29.4% |
| 2020 | $25,424m | +8.8% | $9,139m | 35.9% |
| 2019 | $23,362m | −1.6% | $9,674m | 41.4% |
| 2018 | $23,747m | +3.9% | $10,263m | 43.2% |
| 2017 | $22,849m | −0.6% | $9,973m | 43.6% |
| 2016 | $22,991m | — | $9,794m | 42.6% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Questions about the revenue of Amgen
- How much revenue did Amgen make in fiscal 2025?
- Amgen reported revenue of $36,751m for fiscal 2025, compared with $33,424m in fiscal 2024.
- How much has the revenue of Amgen grown?
- Between fiscal 2016 and fiscal 2025 it went from $22,991m to $36,751m: 59.8% more, an average growth of 5.4% a year.
- What was the best year for revenue at Amgen?
- Of its last 10 fiscal years, fiscal 2025, with $36,751m.
- Where do the figures for Amgen come from?
- From the annual report (Form 10-K) that Amgen files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Amgen files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Amgen: the Amgen page · annual accounts · net income · dividends paid · insider transactions.
Dividend per share of Amgen by fiscal year, with the filing behind every figure: Amgen dividend history.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.